ROIV - Arbutus Biopharma gains after Markman hearing on Thursday in Moderna dispute February, 09 2024 02:05 PM Roivant Sciences Ltd. 2024-02-09 14:05:35 ET More on Arbutus Biopharma Arbutus Biopharma reports 2023 cash position of ~$132M as of Dec. 31, 2023 Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings data for Arbutus Biopharma Financial information for Arbutus Biopharma For further details see: Arbutus Biopharma gains after Markman hearing on Thursday in Moderna dispute